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Introduction
Phenylalanine hydroxylase (PAH) is a cytosolic enzyme
that catalyzes the hydroxylation of phenylalanine to
tyrosine in the presence of tetrahydrobiopterin and
dioxygen. PAH is deficient in phenylketonuria (PKU), a
human autosomal recessive disorder that affects one in
55,071 Taiwanese. To date, more than 440 mutations
in the PAH gene have been reported in the PAHab
database (www.pahab.mcgill.ca) [1].
In PKU, four phenotypic groups have been described,
based on two biochemical parameters, phenylalanine
levels at diagnosis and dietary tolerance of phenylalanine
(defined as the highest phenylalanine intake tolerated
to keep blood phenylalanine levels within therapeutic
ranges). Patients can thus be classified into four
categories according to decreasing severity: classical
PKU, moderate PKU, mild PKU, and mild hyperphenyl-
alaninemia. Classical PKU occurs when the individual
expresses 5% or less of normal PAH activity in hepatic
tissue.
PKU is a treatable disease. If diseased individuals
receive therapeutic regimens, they will have normal
intelligence. In contrast, most untreated individuals
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with PKU will suffer severe mental retardation, eczema,
hypopigmentation, and neurologic symptoms. There-
fore, newborns are routinely screened for PKU in many
countries including Taiwan.
An accurate diagnosis from the newborn screening
program is critical to establish appropriate therapeutic
regimens. With the development of molecular biology,
the diagnostic method has shifted to the molecular
level. In this paper, we report eight pregnant women
with a history of delivering one baby diagnosed with
classical PKU at Taipei Veterans General Hospital who
underwent mid-trimester amniocentesis for prenatal
diagnosis of PKU. We used the polymerase chain reaction
(PCR), automatic sequencing, and linkage analysis with
short tandem repeats (STRs) to detect mutants.
Materials and Methods
Patients and phenotypes
Infants are screened for PKU by measuring blood
phenylalanine during the newborn period, using
either a fluorometric or microbiologic assay. Patients
with classical PKU will eventually demonstrate per-
sistent elevation of phenylalanine at more than 1.0–
1.2 mmol/L after receiving a normal dietary intake of
protein [2].
Eight women who had previously delivered infants
diagnosed with classical PKU were followed up during
a subsequent pregnancy. In the mid-trimester, amnio-
centesis was performed and cells were enriched accord-
ing to standard protocols. At the same time, blood
samples (14–16 mL) from the parents and proband
(infant with PKU) were also collected into ethyl-
enediamine tetraacetic acid (EDTA)-coated tubes.
Mutation analysis
Genomic DNA was extracted from peripheral blood
leukocytes and amniotic cells according to standard
protocols. Previously designed oligonucleotide primers
specific for each exon, intron, enhancer, and the STR in
intron 3 were used for PCR amplification [3]. The intron
3 STR is a repeat of (TCTA)n that can be an allele marker
in genetic analysis. The cDNA sequences were based on
the GenBank reference sequence (NM-000277.1; GI:
4557818) and the A of the ATG translation start site
was numbered as nucleotide +1. Directed sequencing
was performed using the ABI Prism Big Dye dideoxy
chain terminator cycle sequencing kit (Applied Bio-
systems, Foster City, CA, USA). STR genotyping was
performed using PCR amplification in reaction buffer
supplemented with _-32P-dCTP, and products were
resolved on 4% denatured polyacrylamide gel and
analyzed on a phosphorimager (Molecular Dynamics,
Amersham Biosciences Corp, Piscataway, NJ, USA).
Genotyping was performed in a PCR reaction with 5’-
fluorescent dye added to one primer and products were
resolved on 4% denatured polyacrylamide gel using the
ABI Prism 377 automated DNA sequencer (Applied
Biosystems). Genotypes were defined and edited using
GeneScan (version 2.0) and Genotyper (version 2.1)
programs (Applied Biosystems). The enhancer region
was PCR-amplified and products were separated on a
2% agarose gel and visualized by staining with ethidium
bromide. Mutation nomenclature was reported in the
PAHdb (http://www.pahdb.mcgill.ca) and approved
by the Human Genome Variation Society (http://www.
hgvs.org/mutnomen).
Results
As classical PKU is an autosomal recessive disorder, a
genetic defect in both PAH alleles is necessary for the
disease to be present. Individuals carrying only one
mutant allele are considered disease carriers. The
genotypes for the eight pregnant women, fetuses, fa-
thers, and probands are shown in the Table.
In Family 1, analysis of the exon 12 sequence from
the proband revealed a mutation at amino acids 413
and 408, changing an arginine to proline and an arginine
to glutamine, respectively. The mutant alleles were
derived from his parents independently (R413P from
father and R408Q from mother). Fortunately, analysis
of amniotic cells in this pregnancy revealed that both
alleles were normal, so the fetus was diagnosed as
normal.
We also performed intron 3 STR linkage analysis in
this case. The proband had two 242 bp/238 bp STRs
and both were linked to mutant alleles. We successfully
traced the source of these mutant forms and found that
the 242 bp STR came from the father and the 238 bp
STR came from the mother. Amniotic cell analysis in this
pregnancy revealed that both alleles were wild type
(Figure 1). Both detection modalities revealed that the
fetus was free from PKU.
In Family 2, the proband had a mutation from
adenine to guanine at the 96th nucleotide of exon 6 in
both alleles (E6nt-96AAG). Both the father and mother
carried only a single mutant allele, suggesting that each
proband mutant allele was derived from the father and
mother separately. Analysis of amniotic cells in this
pregnancy revealed a single allele mutation but it was
not possible to identify the source since both the father
and mother carried the same mutation. We concluded
that this fetus was a carrier.
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In Family 3, proband genotype showed a mutation
at amino acid 241 from arginine to cysteine in both exon
7 alleles. The parents were both disease carriers and the
fetus was also a disease carrier. The findings were similar
in Families 4 and 5, and the fetus was a disease carrier
based on sequencing findings.
In Family 6, exon 7 of the proband had one allele
mutation (G257V) but the other allele was normal
(G257). This mutated allele came from the father. Since
PKU is an autosomal recessive disease, a mutation in
the other allele should be present. Therefore, intron 3
STR analysis was used to identify the second mutation.
We identified two mutant alleles and proved that one
derived from the father and the other from the mother
(238 bp from the father and 246 bp from the mother,
respectively). Using the STR marker, the fetus was
diagnosed as a carrier (Figure 2).
In Family 7, exon 12 sequence analysis identified one
allele mutation (R408Q) in the proband and father. Am-
niotic cell analysis also revealed the R408Q mutation
in one allele. A PAH gene enhancer deletion has been
identified as associated with PKU [4]. The deleted
enhancer disturbs the production of PAH and this
mutation can be used for genetic analysis. The normal
enhancer will produce 4.7 kb and 230 bp PCR fragments
with appropriate primers. In contrast, the deleted
enhancer will produce a 350 bp PCR fragment. Using
this strategy, we found that the proband carried a
deleted enhancer from the mother. Subsequently, the
fetus was shown to carry a deleted enhancer from the
mother (Figure 3). The fetus also carried the exon 12
mutation (R408Q) from the father and was diagnosed
as a diseased infant.
In Family 8, exon 6 analysis detected one mutant
allele (E6nt-96AAG) in the proband and father. The
PAH marker was used to trace the other mutation.
Intron 3 STR was used but it also failed to identify the
Table. Summary of eight cases
Family Father Mother Proband Fetus
1 R413P/WT R408Q/WT R413P/R408Q WT/WT
    STR 242 bp/WT 238 bp/WT 242 bp/238 bp WT/WT
2 E6nt-96AAG/WT E6nt-96AAG/WT E6nt-96AAG/E6nt-96AAG E6nt-96AAG/WT
3 R241C/WT R241C/WT R241C/R241C R241C/WT
4 R408Q/WT R241C/WT R408Q/R241C R241C/WT
5 R408Q/WT A434D/WT R408Q/A434D A434D/WT
6 G257V/WT ND/WT G257V/ND G257V/WT
    STR 238 bp/WT 246 bp/WT 238 bp/246 bp 238 bp/WT
7 R408Q/WT enh6/WT R408Q/enh6 R408Q/enh6
8 E6nt-96AAG/WT ND/WT E6nt-96AAG/ND WT/?
    STR 242 bp/230 bp 238 bp/238 bp 242 bp/238 bp 230 bp/238 bp
R = arginine; P = proline; WT = wild type; Q = glutamine; STR = short tandem repeat; bp = base pairs; E6 = exon 6; nt = nucleotide; AAG = adenine
to guanine mutation; C = cysteine; D = aspartate; V = valine; ND = not determined; enh6 = enhancer deletion.
Figure 1. Family 1 intron 3 short tandem repeat analysis. Lane
1: father (242 bp/wild type); Lane 2: mother (238 bp/wild
type); Lane 3: proband (242 bp/238 bp); Lane 4: fetus (wild
type/wild type).
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Figure 2. Family 6 intron 3 short tandem repeat (STR) analysis.
Proband STR revealed 238 bp/246 bp and two mutated
alleles, the 238 bp from the father and 246 bp from the mother.
Fetal STR revealed 238 bp and 233 bp. Line 1: father (238 bp/
wild type); Line 2: mother (246 bp/wild type); Line 3: proband
(238 bp/246 bp); Line 4: fetus (238 bp/wild type).
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mutant allele from the mother since proband, mother,
and father carried the 238 bp fragment. The fetus
carried a normal allele from the father (E6nt-96A and
intron 3, 230 bp), but the allele from the mother could
not be identified and the true genotype was not identified.
Discussion
PKU has frequently been described as a paradigm of a
Mendelian disorder and classified as an autosomal
recessive disorder. It was the first identified mental
retardation caused by a metabolic disorder. It is also the
first genetic disorder of the central nervous system that
can be fully prevented by modification of an external
factor (i.e. diet) [5]. In addition, it is the first disorder
that can successfully be diagnosed by universal neo-
natal screening [6].
The prevalence of hyperphenylalaninemia caused
by PAH deficiency (1/55,071), especially of classical
PKU (1/413,035), is low in Taiwan compared to that in
Caucasian populations [7]. Conventionally, patients
are evaluated by phenotypes based on several parame-
ters, including pretreatment blood phenylalanine
levels, dietary phenylalanine tolerance, and metabolism
of intravenously administered labeled phenylalanine
[8]. With advanced molecular biology techniques,
genotypic evaluation is a good predictor of biochemi-
cal phenotype in most patients [2]. Mutation analysis
in PAH genes is a routine diagnostic service in many
countries. In this study, we used the same strategy for
prenatal screening at mid-trimester amniocentesis in
eight pregnant women who had delivered a baby diag-
nosed as having classical PKU.
For Families 1–6, we used a single pair of primers to
screen a specific gene based on the genotype of the
defect in the proband. We successfully traced the mutant
allele in parents and predicted the fetus genotype. STR
marker analysis allowed further determination of allele
status. For example, in Family 1, it was used to confirm
the genotype.
Although the whole PAH DNA sequence can pro-
vide accurate data for mutation tracing, this is time
consuming and expensive. Using different markers
(specific allele locus mutation detection) in a stepwise
manner based on data from the mutation spectrum in
the local population provides a more economical
approach [9,10], without compromising the results of
gene tracing and confirming fetal genotype.
Complete PKU mutation data from several
populations can be searched in the PAHab database
(www.pahab.mcgill.ca) [1]. In most Caucasian popu-
lations, R408W is the most common PAH mutation,
followed by IVS12+1GAA and IVS10-11GAA,
representing up to 80%, 38%, and 30% of the
PAH mutations in certain areas [7,11,12]. Other-
wise, PAH mutations are quite diverse. The mutation
spectrum in the Taiwanese population has recently
been reported [13]. R241C is the most common mu-
tation followed by R408Q. The remaining mutations
are rare. In this paper, from studying eight mutations
(proband genotype), we also confirmed the most
frequent mutant forms as R408Q (n = 4, 25%) and
R241C (n = 3, 19%). The other mutant sites were R413P
(n = 1, 6%), A434D (n = 1, 6%) and G257V (n = 1, 6%).
Therefore, we suggest that future prenatal mutation
screening can be based on the mutation spectrum of the
report by Chien et al [13].
In this paper, we provided our experience in detecting
mutant PKU alleles in amniotic and peripheral blood
cells. Using primers specific for the target allele locus
step by step, the mutation can be identified and the
inherent relationship can also be followed. This accurate
diagnostic modality in PKU prenatal screening confirmed
the mutation spectrum in Taiwan [13] and provides the
ability to predict the phenotype in a fetus with PAH
deficiency, to enable the design and early implementation
of a patient-rational dietary regimen, and to facilitate
genetic counseling in this ethnic group.
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